|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Allergopharma Joachim Ganzer KG |
|---|---|
| Information provided by: | Allergopharma Joachim Ganzer KG |
| ClinicalTrials.gov Identifier: | NCT00263952 |
Purpose
The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy
| Condition | Intervention | Phase |
|---|---|---|
|
Bee Venom Allergy |
Biological: bee venom |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies. |
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | Al0202ig |
| Study First Received: | December 9, 2005 |
| Last Updated: | July 16, 2008 |
| ClinicalTrials.gov Identifier: | NCT00263952 History of Changes |
| Health Authority: | Germany: Paul-Ehrlich-Institut |
|
Bee venom allergy Specific immunotherapy |
|
Hypersensitivity Immune System Diseases |